Cerner Enviza to Accelerate Therapies and Improve Patient Outcomes
Cerner announces the launch of a new operating unit, Cerner Enviza, that offers data-driven solutions and research services to help bring clarity to multi-dimensional data through real-world evidence and insights. The combined expertise of the Cerner and Kantar Health teams is expected to help accelerate discovery, development and deployment of therapies and advance clinical research and the life sciences industry to improve everyday health.
Today, new therapies can take on average 17 years and $2.5 billion to finally reach patients. Cerner Enviza was established to unlock the power of data and a network of research-ready health systems to help get therapies to patients more quickly and at less expense. In addition, a key focus will be on broadening the availability and participation in trials to help achieve more equitable results. For example, according to one study only 3% of physicians and patients participate in trials and only a fraction of eligible patients receive the new treatments.
“The true promise of the digital age is to use data to improve everyday health around the world,” said David Feinberg, M.D., president and CEO, Cerner. “Healthcare is far too complex, inefficient and expensive. We have to break down industry silos and evolve from simply accumulating data to generating meaningful insights that can accelerate therapy development. With Cerner Enviza, we can arm researchers with diverse tools and datasets to help them address these challenges and help change the way we develop and deliver care for our patients.”
For more than 20 years, Cerner has offered research and real-world data solutions to help caregivers and investigators launch or advance their efforts. Kantar Health worldwide has spent years helping life sciences researchers leverage data – both quantitative and qualitative – to better understand patient and treatment journeys. Cerner Enviza is dedicated to not only connecting – but bridging – industry and technology boundaries.
“With Cerner Enviza, we bring together the expertise, assets and capabilities of Kantar Health with Cerner’s technology and access to a large collection of deidentified patient health data,” said Mike Kelly, Global Head of Cerner Enviza. “Our approach unites the life sciences and healthcare providers to support research and trial opportunities across this ecosystem. The goal is to significantly reduce the timeframe and cost from idea to therapy delivery to help achieve better patient outcomes.”
Cerner Enviza aims to accelerate the discovery, development and delivery of extraordinary insights and therapies to improve everyday health for people globally. By combining decades of innovation, life sciences knowledge and collaborative research, Cerner Enviza provides data-driven solutions and expertise that helps bring remarkable clarity to healthcare’s most important decisions.